Skip to main content
SpringerLink
Log in

Type 2 Diabetes

  • Chapter
Early Diagnosis and Treatment of Endocrine Disorders

Part of the book series: Contemporary Endocrinology ((COE))

  • 153 Accesses

Abstract

Impaired glucose tolerance (IGT), a precursor to type 2 diabetes, has received important attention in the past year. Two large clinical trials have suggested that individuals with IGT can be prevented, or at least delayed, from progressing to type 2 diabetes and its complications (1–3). The data from these trials are important in regard to the well-publicized national and worldwide epidemics of type 2 diabetes. To discuss early diagnosis and early treatment of type 2 diabetes means discussing IGT—who to screen and how to approach the therapy of IGT (4). This chapter primarily discusses IGT, its recognition, how and who to screen, and its treatment. Finally, we suggest measures for pre-IGT recognition of the at-risk population, and we also suggest preventive therapy even before IGT develops (5–7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623–634.

    Google Scholar 

  2. The Diabetes Prevention Program: Baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care 2000;23:1619–1629.

    Google Scholar 

  3. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.

    PubMed  CAS  Google Scholar 

  4. Narayan KM, Bowman B A, Engelgau ME. Prevention of type 2 diabetes. BMJ 2001;323:63–64.

    PubMed  CAS  Google Scholar 

  5. Perry RC, Baron AD. Impaired glucose tolerance. Why is it not a disease? Diabetes Care 1999;22:883–885.

    PubMed  CAS  Google Scholar 

  6. Alberti KG. The clinical implications of impaired glucose tolerance. Diabet Med 1996; 13:927–937.

    PubMed  CAS  Google Scholar 

  7. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997;20:1562–1568.

    PubMed  CAS  Google Scholar 

  8. Heine RJ, Mooy JM. Impaired glucose tolerance and unidentified diabetes. Postgrad Med J 1996;72:67–71.

    PubMed  CAS  Google Scholar 

  9. Johnson KC, Graney MJ, Applegate WB, Kitabchi AE, Runyan JW, Shorr RI. Prevalence of undiagnosed non-insulin-dependent diabetes mellitus and impaired glucose tolerance in a cohort of older persons with hypertension. J Am Geriatr Soc 1997;45:695–700.

    PubMed  CAS  Google Scholar 

  10. Uusitupa M, Louheranta A, Lindstrom J, et al. The Finnish Diabetes Prevention Study. Br J Nutr 2000;83 Suppl 1:S137-S142.

    PubMed  CAS  Google Scholar 

  11. Harris TJ, Cook DG, Wicks PD, Cappuccio FP. Impact of the new American Diabetes Association and World Health Organisation diagnostic criteria for diabetes on subjects from three ethnic groups living in the UK. Nutr Metab Cardiovasc Dis 2000;10:305–309.

    PubMed  CAS  Google Scholar 

  12. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–1470.

    PubMed  CAS  Google Scholar 

  13. Metcalf PA, Scragg RK. Comparison of WHO and ADA criteria for diagnosis of glucose status in adults. Diabetes Res Clin Pract 2000;49:169–180.

    PubMed  CAS  Google Scholar 

  14. Bolli G, Compagnucci P, Cartechini MG, et al. HbAl in subjects with abnormal glucose tolerance but normal fasting plasma glucose. Diabetes 1980;29:272–277.

    PubMed  CAS  Google Scholar 

  15. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001;50:150–158.

    PubMed  CAS  Google Scholar 

  16. Greenbaum CJ, Cuthbertson D, Krischer JP. Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 2001;50:470–476.

    PubMed  CAS  Google Scholar 

  17. Shaw JE, Zimmet PZ, de Courten M, et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999;22:399–402.

    PubMed  CAS  Google Scholar 

  18. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920–924.

    PubMed  CAS  Google Scholar 

  19. Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000;49:975–980.

    PubMed  CAS  Google Scholar 

  20. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.

    PubMed  CAS  Google Scholar 

  21. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318–368.

    PubMed  CAS  Google Scholar 

  22. Ipp E. Impaired glucose tolerance: the irrepressible alpha-cell? Diabetes Care 2000;23:569–570.

    PubMed  CAS  Google Scholar 

  23. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047–4058.

    PubMed  CAS  Google Scholar 

  24. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–794.

    PubMed  CAS  Google Scholar 

  25. Stolk RP, Pols HA, Lamberts SW, de Jong PT, Hofman A, Grobbee DE. Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. Am J Epidemiol 1997;145:24–32.

    CAS  Google Scholar 

  26. Rewers M, Hamman RF. Risk factors for non-insulin-dependent diabetes. In: Harris ML, Cowie CC, Stern MF, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America, 2nd ed. NIH publication no. 95–1468. NIH, Bethesda, MD, 1995, pp. 179–220.

    Google Scholar 

  27. Lee ET, Howard BV, Savage PJ, et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45–74 years. Diabetes Care 1995;18:599–610.

    PubMed  CAS  Google Scholar 

  28. Wing RR, Goldstein MG, Acton KJ, et al. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 2001;24:117–123.

    PubMed  CAS  Google Scholar 

  29. Kjos SL, Buchanan TA. Gestational diabetes mellitus. N Engl J Med 1999;341:1749–1756.

    PubMed  CAS  Google Scholar 

  30. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790–797.

    PubMed  CAS  Google Scholar 

  31. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403–408.

    PubMed  CAS  Google Scholar 

  32. Haffner SM, Hazuda HP, Mitchell BD, et al. Increased incidence of type II diabetes mellitus in Mexican Americans. Diabetes Care 1991;14:102–108.

    PubMed  CAS  Google Scholar 

  33. Fujimoto WY. Diabetes in Asian and Pacific Islander Americans. In: Harris MI, ed. Diabetes in America. NIH publication no. 95–1468. National Institutes of Health, Bethesda, MD, 1995, pp. 661–681.

    Google Scholar 

  34. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Statistics 1995. NIH publication no. 96. National Institutes of Health, Bethesda, MD, 1995, pp. 3926.

    Google Scholar 

  35. Bergman RN, Watanabe R, Rebrin K, Ader M, Steil G. Toward an integrated phenotype in pre-NIDDM. Diabet Med 1996;13:S67-S77.

    PubMed  CAS  Google Scholar 

  36. Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 1996;19:1018–1030.

    PubMed  CAS  Google Scholar 

  37. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991;338:774–778.

    PubMed  CAS  Google Scholar 

  38. Manson JE, Nathan DM, Krolweski AS, et al. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992;268:63–67.

    PubMed  CAS  Google Scholar 

  39. Helmrich SP, Ragland DR, Leung RW, et al. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991;325:147–152.

    PubMed  CAS  Google Scholar 

  40. Hamman RF. Genetic and enviromental determinants of non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992;8:287–338.

    PubMed  CAS  Google Scholar 

  41. DeFronzo RA. Lilly lecture 1987. The triumvirate: (3-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667–687.

    PubMed  CAS  Google Scholar 

  42. Knowler WC, Narayan KM, Hanson RL, et al. Preventing non-insulin-dependent diabetes. Diabetes 1995;44:483–488.

    PubMed  CAS  Google Scholar 

  43. Campbell PJ, Carlson MG. Impact of obesity on insulin action in NIDDM. Diabetes 1993;42:405–410.

    PubMed  CAS  Google Scholar 

  44. Wing RR, Blair EH, Bononi P, et al. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994;17:30–36.

    PubMed  CAS  Google Scholar 

  45. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986;35:990–998.

    PubMed  CAS  Google Scholar 

  46. Maron DJ, Fair JM, Haskelll WL. Saturated fat intake and insulin resistance in men with coronary artery disease. Circulation 1991;84:2020–2027.

    PubMed  CAS  Google Scholar 

  47. Parillo M, Rivellese AA, Ciardullo AV, et al. A high-monounsaturated-fat/low-carbohy-drate diet improves peripheral insulin sensitivity in non-insulin dependent diabetic patients. Metabolism 1992;41:1373–1378.

    PubMed  CAS  Google Scholar 

  48. Kriska AM, Bennett PH. An epidemiological perspective of the relationship between physical activity and NIDDM: from activity assessment to intervention. Diabetes Metab Rev 1992;8:355–372.

    PubMed  CAS  Google Scholar 

  49. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 1991;34:891–898.

    PubMed  CAS  Google Scholar 

  50. Tritos NA, Mantzoros CS. Clinical review 97: syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998;83:3025–3030.

    PubMed  CAS  Google Scholar 

  51. Barrett-Connor E. Epidemiology, obesity, and non-insulin-dependent diabetes mellitus. Epidemiol Rev 1989;11:172–181.

    PubMed  CAS  Google Scholar 

  52. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986–1998. JAMA 2001;286:2845–2848.

    PubMed  CAS  Google Scholar 

  53. Jones KL, Arslanian S, Peterokova VA, Park J-S, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes. Diabetes Care 2002;25:89–94.

    PubMed  CAS  Google Scholar 

  54. Samos LF, Roos B A. Diabetes mellitus in older persons. Med Clin North Am 1998;82:791–803.

    PubMed  CAS  Google Scholar 

  55. Ford ES, Giles, WH, Dietz WH. Prevalence of the metabolic syndrome amoung US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356–360.

    PubMed  Google Scholar 

  56. Kahn SE, Porte D Jr. Pathophysiology of type II diabetes mellitus. In: Porte D Jr, Sherwin RS, eds. Diabetes Mellitus. Appleton & Lange, Stamford, CT, 1996, pp. 487–512.

    Google Scholar 

  57. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. (3-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabetes Med 1996;15:290–296.

    Google Scholar 

  58. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1231–1239.

    PubMed  CAS  Google Scholar 

  59. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777–783.

    PubMed  CAS  Google Scholar 

  60. Ward WK, Wallum BJ, Beard JC, Taborsky GJ Jr, Porte D Jr. Reduction of glycemic potentiation: a sensitive indicator of (3-cell loss in partially pancreatectomized dogs. Diabetes 1988;37:723–729.

    PubMed  CAS  Google Scholar 

  61. Goldfine ID. The insulin receptor; molecular biology and transmembrane signaling. Endocr Rev 1987;8:235–255.

    PubMed  CAS  Google Scholar 

  62. Kahn, CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994;43:1066–1084.

    PubMed  CAS  Google Scholar 

  63. Lee, JS, Pilch, PF. The insulin receptor—structure, function, and signaling. Am J Physiol 1994;266:C319-C334.

    PubMed  CAS  Google Scholar 

  64. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem 1999;274:1865–1868.

    PubMed  CAS  Google Scholar 

  65. White M, Kahn CR. The insulin signaling system. J Biol Chem 1994;269:1–4.

    PubMed  CAS  Google Scholar 

  66. White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 1998;53:119–138.

    PubMed  CAS  Google Scholar 

  67. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000;106:165–169.

    PubMed  CAS  Google Scholar 

  68. Kido Y, Nakae J, Accili D. Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001;86:972–979.

    PubMed  CAS  Google Scholar 

  69. Taylor SI, Kadowaki T, Kadowaki H, Accili C, Cama A, McKeon C. Mutations in insulin receptor gene in insulin resistant patients. Diabetes Care 1990;13:257–279.

    PubMed  CAS  Google Scholar 

  70. Taylor SI, Cama A, Accili D, et al. Mutations in the insulin receptor gene. Endocr Rev 1992;13:566–595.

    PubMed  CAS  Google Scholar 

  71. O’Rahilly S, Moller DE. Mutant insulin receptors in syndromes of insulin resistance. Clin Endocrinol 1992;36:121–132.

    Google Scholar 

  72. Watson RT, Pessin JE. Subcellular compartmentalization and trafficking of the insulin-responsive glucose transporter, GLUT4. Exp Cell Res 2001;271:75–83.

    PubMed  CAS  Google Scholar 

  73. Saltiel AR. Diverse signaling pathways in the cellular actions of insulin. Am J Physiol 1996;270:E375-E385.

    PubMed  CAS  Google Scholar 

  74. Watson RT Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res 2001;56:175–193.

    PubMed  CAS  Google Scholar 

  75. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 1999;104:733–741.

    PubMed  CAS  Google Scholar 

  76. Araki E, Lipes MA, Patti ME, et al. Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene. Nature 1994;372,186–190.

    PubMed  CAS  Google Scholar 

  77. Tamemoto H, Kadowaki T, Tobe K, et al. 1994. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182–186.

    PubMed  CAS  Google Scholar 

  78. Kubota N, Tobe K, Terauchi Y, et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 2000;49:1880–1889.

    PubMed  CAS  Google Scholar 

  79. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999;107:119–125.

    PubMed  CAS  Google Scholar 

  80. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of iKkbeta. Science 2001;293:1673–1677.

    PubMed  CAS  Google Scholar 

  81. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437–446.

    PubMed  CAS  Google Scholar 

  82. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999;96:329–339.

    PubMed  CAS  Google Scholar 

  83. Medalie JH, Papeir CM, Goldbourt U, Herman JB. Major factors in the development of diabetes mellitus in 10,000 men. Arch Intern Med 1975;135:811–817.

    PubMed  CAS  Google Scholar 

  84. Gulli G, Ferrannini E, Stern M, Haffner SM, DeFronzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican American parents. Diabetes 1992;41:1575–1586.

    PubMed  CAS  Google Scholar 

  85. Haffner SM. Risk factors for non-insulin-dependent diabetes mellitus. J Hypertens 1995;13:S73-S76.

    CAS  Google Scholar 

  86. Eastman RC, Cowie CC, Harris MI. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk. Diabetes Care 1997;20:127–128.

    PubMed  CAS  Google Scholar 

  87. Balkau B, Eschwege E, Papoz L, et al. Risk factors for early death in non-insulin-dependent diabetes and men with known glucose tolerance status. BMJ 1993;207:295–299.

    Google Scholar 

  88. Sadd MF, Knowler WC, Pettitt DJ, Nelson RG, Bennett PH. The natural history of impaired glucose tolerance in Pima Indians. N Engl J Med 1988;319:1500–1506.

    Google Scholar 

  89. Alarcon de la Lastra C, Barranco MD, Motilva V, Herrerias JM. Mediterranean diet and health: biological importance of olive oil. Curr Pharm Des 2001;7:933–950.

    Google Scholar 

  90. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000;342:1392–1398.

    PubMed  CAS  Google Scholar 

  91. Savage PJ, Bennion LJ, Flock EV, et al. Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus. J Clin Endocrinol Metab 1979;48:999–1007.

    PubMed  CAS  Google Scholar 

  92. Eriksson KF, Saltin B, Lindgarde F. Increased skeletal muscle capillary density precedes diabetes development in men with impaired glucose tolerance. A 15-year follow-up. Diabetes 1994;43:805–808.

    PubMed  CAS  Google Scholar 

  93. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544.

    PubMed  CAS  Google Scholar 

  94. Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998;21:350–359.

    PubMed  CAS  Google Scholar 

  95. Scheen AJ, Letiexhe MR, Lefebvre PJ. Effects of metformin in obese patients with impaired glucose tolerance. Diabetes Metab Rev 1995;11(Suppl 1):S69–S80.

    Google Scholar 

  96. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355:1008–1010.

    PubMed  CAS  Google Scholar 

  97. Mayer-Davis EJ. Low-fat diets for diabetes prevention. Diabetes Care 2001;24:613–614.

    PubMed  CAS  Google Scholar 

  98. O’Dea K. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle. Diabetes 1984;33:596–603.

    PubMed  Google Scholar 

  99. Madigan C, Ryan M, Owens D, Collins P, Tomkin GH. Dietary unsaturated fatty acids in type 2 diabetes: higher levels of postprandial lipoprotein on a linoleic acid-rich sunflower oil diet compared with an oleic acid-rich olive oil diet. Diabetes Care 2000;23:1472–1477.

    PubMed  CAS  Google Scholar 

  100. Lillioja S. Impaired glucose tolerance in Pima Indians. Diabet Med 1996; 13:S 127-S132.

    Google Scholar 

  101. Sundquist J, Winkleby MA. Cardiovascular risk factors in Mexican American adults: a transcultural analysis of NHANES III, 1988–1994. Am J Public Health 1999;89:723–730.

    PubMed  CAS  Google Scholar 

  102. Sundquist J, Winkleby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988–1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2001;49:109–116.

    PubMed  CAS  Google Scholar 

  103. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 2001;24:619–624.

    PubMed  CAS  Google Scholar 

  104. Long SD, O’Brien K, MacDonald KG, Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 1994;17:372–375.

    PubMed  CAS  Google Scholar 

  105. Bourn DM. The potential for lifestyle change to influence the progression of impaired glucose tolerance to non-insulin-dependent diabetes mellitus. Diabet Med 1996;13:938–945.

    PubMed  CAS  Google Scholar 

  106. Lewis V. Polycystic ovary syndrome. A diagnostic challenge. Obstet Gynecol Clin North Am 2001;28:1–20.

    PubMed  CAS  Google Scholar 

  107. Zacur HA. Polycystic ovary syndrome, hyperandrogenism, and insulin resistance. Obstet Gynecol Clin North Am 2001;28:21–33.

    PubMed  CAS  Google Scholar 

  108. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–861.

    PubMed  CAS  Google Scholar 

  109. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:341–359.

    PubMed  CAS  Google Scholar 

  110. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:99–109.

    PubMed  CAS  Google Scholar 

  111. Nelson VL, Qinkn K, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925–5933.

    PubMed  CAS  Google Scholar 

  112. Larsson H, Ahren B. Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women. Diabetes Care 1996;19:1399–1403.

    PubMed  CAS  Google Scholar 

  113. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:111–133, vii.

    PubMed  CAS  Google Scholar 

  114. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541–549.

    PubMed  CAS  Google Scholar 

  115. Bailey CJ, Turner RC. Metformin. N Engl J Med 1995;334:574–579.

    Google Scholar 

  116. Stumvoll M, Nurjhan N, Perrieloo G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550–554.

    PubMed  CAS  Google Scholar 

  117. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992;15:792–805.

    PubMed  CAS  Google Scholar 

  118. Iuorno MJ, Nestler JE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:153–164.

    PubMed  CAS  Google Scholar 

  119. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.

    PubMed  CAS  Google Scholar 

  120. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–654.

    PubMed  CAS  Google Scholar 

  121. Hoeger K. Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:85–97, vi-vii.

    PubMed  CAS  Google Scholar 

  122. Lindeman RD, Romero LJ, Hundley R, et al. Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. Diabetes Care 1998;21:959–966.

    PubMed  CAS  Google Scholar 

  123. Weitzman S. Impaired fasting glucose is not a risk factor for cardiovascular mortality. Diabetes Care 1999;22:2104.

    Google Scholar 

  124. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 2001;86:5366–5371.

    PubMed  CAS  Google Scholar 

  125. Arner P. Not all fat is alike. Lancet 1998;351:1301–1302.

    PubMed  CAS  Google Scholar 

  126. Kulkarni RN, Wang ZL, Wang RM, et al. Leptin reapidly suppresses insulin release from insulinoma cells, rat and human islets, in vivo, in mice. J Clin Invest 100:2729–2736, 1997.

    PubMed  CAS  Google Scholar 

  127. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.

    PubMed  CAS  Google Scholar 

  128. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.

    PubMed  CAS  Google Scholar 

  129. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002;13:18–23.

    PubMed  CAS  Google Scholar 

  130. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875–1881.

    PubMed  CAS  Google Scholar 

  131. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947–953.

    PubMed  CAS  Google Scholar 

  132. Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997;20:188–193.

    PubMed  CAS  Google Scholar 

  133. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ 2000;321:252–253.

    PubMed  CAS  Google Scholar 

  134. Olefsky JM. Treatment of insulin resistance with peroxisome prol iterator-activated receptor gamma agonists. J Clin Invest 2000;106:467–472.

    PubMed  CAS  Google Scholar 

  135. Festa A, D’Agostino R, Jr., Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vase Biol 1999;19:562–568.

    CAS  Google Scholar 

  136. Festa A, D’Agostino R Jr, Mykkanen L, Tracy R, Howard BV, Haffner SM. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vase Biol 1999;19:605–610.

    CAS  Google Scholar 

  137. Haffner SM, D’Agostino R, Jr., Mykkanen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999;22:562–568.

    PubMed  CAS  Google Scholar 

  138. Lindahl B, Nilsson TK, Jansson JH, Asplund K, Hallmans G. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J Intern Med 1999;246:105–112.

    PubMed  CAS  Google Scholar 

  139. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000;283:221–228.

    PubMed  CAS  Google Scholar 

  140. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000;16:192–201.

    PubMed  CAS  Google Scholar 

  141. Eastman RC, Cowie CC, Harris MI. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk. Diabetes Care 1997;20:127–128.

    PubMed  CAS  Google Scholar 

  142. Seibaek M, Sloth C, Vallebo L, et al. Glucose tolerance status and severity of coronary artery disease in men referred to coronary arteriography. Am Heart J 1997;133:622–629.

    PubMed  CAS  Google Scholar 

  143. The Diabetes Prevention Program (DPP) Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346:393–403.

    Google Scholar 

  144. The Diabetes Prevention Program (DPP) Research Group: The diabetes prevention program (DPP): Description of lifestyle intervention. Diabetes Care 2002;25:2165–2171.

    Google Scholar 

  145. Moore LLVAJ, Wilson P, D’Agostino RB, Finkle WD, Elliso RC. Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus? Epidemiology 2000; 11:269–273.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Preethi Srikanthan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey E. Pessin PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert S. Bar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology and Metabolism Department of Internal Medicine, The University of Iowa School of Medicine, Iowa City, IA, USA

    Robert S. Bar MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Srikanthan, P., Pessin, J.E., Bar, R.S. (2003). Type 2 Diabetes. In: Bar, R.S. (eds) Early Diagnosis and Treatment of Endocrine Disorders. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-378-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-378-1_5

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-414-2

  • Online ISBN: 978-1-59259-378-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation